Takeda Pharmaceuticals North America, Inc. recalls CONTRAVE (naltrexone HCl and bupropion HCl )extended-release tablets, 8 mg/ 90 mg, 120-count bottle, Rx only, Manufactu…
- Recall date
- May 21, 2015
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-1206-2015
- FDA classification
- Class II
- Brand / firm
- Takeda Pharmaceuticals North America, Inc.
- Sold / distributed
- Nationwide
Why it was recalled
Failed Tablet/Capsule Specifications: Potential tablet defect of broken tablets and/or equatorial splitting of the bilayer tablets into the two drug components.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
CONTRAVE (naltrexone HCl and bupropion HCl )extended-release tablets, 8 mg/ 90 mg, 120-count bottle, Rx only, Manufactured for Orexigen Therapeutics, Inc., La Jolia, CA 92037, Distributed by Takeda Pharmaceuticals America, Inc., Deerfield, IL 60015, NDC 64764-890-99.
Get recall alerts
Free email alert whenever Takeda Pharmaceuticals North America, Inc. has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Takeda Pharmaceuticals North America, Inc.